These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37511437)

  • 1. Calcium-Sensing Receptor Expression in Breast Cancer.
    Busic-Pavlek I; Dumic-Cule I; Kovacevic L; Milosevic M; Delimar P; Korsa L; Marusic Z; Prutki M
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.
    Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S
    J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of B-cell lymphoma 2 immunoexpression in invasive carcinoma of breast, no special type with hormone receptor status, proliferation index, and molecular subtypes.
    Azmat H; Faridi J; Habib HM; Bugti UJ; Sheikh AK; Riaz SK
    J Cancer Res Ther; 2022 Dec; 18(Supplement):S313-S319. PubMed ID: 36510982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 is a prognostic marker for hormone receptor positive tumors.
    Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
    Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases.
    Yamanouchi K; Kuba S; Eguchi S
    Surg Today; 2020 Jul; 50(7):657-663. PubMed ID: 31190183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
    Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
    World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
    Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
    Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
    Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
    Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
    Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
    Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of PKM2 Expression With HER2/neu and Additional Breast Cancer Biomarkers and its Prognostic Significance.
    Al-Qudah MA; Al-Keilani MS; Obeidat M; Haddad HK; Bdeir R; Samman LM
    Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):363-370. PubMed ID: 37212690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
    Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study.
    Kakudji BK; Mwila PK; Burger JR; du Plessis JM; Naidu K
    Pan Afr Med J; 2021; 38():85. PubMed ID: 33889251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
    Shokouh TZ; Ezatollah A; Barand P
    Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.